Pharmaceutical manufacturers Novo Nordisk and Sanofi on Tuesday laid out their cases for the next phase of the legal battle over their conditions on 340B pricing when covered entities use contract pharmacies. The cases are before the U.S. Court of Appeals for the Third Circuit in Philadelphia, Pa.
The two companies are appealing a federal district judge’s Nov. 5 ruling that
Novo Nordisk and Sanofi on Tuesday laid out their cases for the next phase of the legal battle over their conditions on 340B pricing when covered entities use contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
